Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BDRX Biodexa Pharmaceuticals	$6.91 -1.1%	$8.86	$5.85 ▼ $163.10	$25.54M	0.98	39,521 shs	23,501 shs
JATT JATT Acquisition	$1.47 +4.3%	$1.34	$7.80 ▼ $12.38	$25.36M	N/A	41,322 shs	145,631 shs
MIRA MIRA Pharmaceuticals	$1.49 +1.4%	$1.41	$0.73 ▼ $2.70	$28.03M	1.77	788,202 shs	209,564 shs
NLSP NLS Pharmaceutics	$2.42 +13.6%	$2.26	$1.30 ▼ $7.44	$7.66M	0.15	168,023 shs	314,386 shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BDRX Biodexa Pharmaceuticals	+1.45%	+0.14%	-20.02%	-46.64%	+698,999,900.00%
JATT JATT Acquisition	-0.70%	-6.00%	+7.63%	+16.53%	-58.41%
MIRA MIRA Pharmaceuticals	+3.52%	-3.92%	+14.84%	+10.53%	-30.33%
NLSP NLS Pharmaceutics	+2.40%	+12.11%	+1.43%	+29.09%	+1,027.58%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BDRX Biodexa Pharmaceuticals	0.1979 of 5 stars	0.0	2.0	0.0	0.0	3.0	0.0	0.0
JATT JATT Acquisition	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
MIRA MIRA Pharmaceuticals	2.3507 of 5 stars	3.8	2.0	0.0	0.0	3.1	0.0	0.6
NLSP NLS Pharmaceutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BDRX Biodexa Pharmaceuticals	0.00	N/A	N/A	N/A
JATT JATT Acquisition	0.00	N/A	N/A	N/A
MIRA MIRA Pharmaceuticals	3.50	Strong Buy	$17.00	1,040.94% Upside
NLSP NLS Pharmaceutics	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BDRX Biodexa Pharmaceuticals	$470K	53.66	N/A	N/A	$2.91 per share	2.37
JATT JATT Acquisition	N/A	N/A	$0.05 per share	27.08	($0.53) per share	N/A
MIRA MIRA Pharmaceuticals	N/A	N/A	N/A	N/A	$0.13 per share	N/A
NLSP NLS Pharmaceutics	N/A	N/A	N/A	N/A	($0.37) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BDRX Biodexa Pharmaceuticals	-$7.32M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A
JATT JATT Acquisition	$6.85M	N/A	0.00	∞	N/A	N/A	-49.58%	2.84%	N/A
MIRA MIRA Pharmaceuticals	-$7.85M	-$0.51	N/A	N/A	N/A	N/A	-341.08%	-272.93%	N/A
NLSP NLS Pharmaceutics	-$1.98M	N/A	0.00	∞	N/A	N/A	N/A	N/A	8/15/2025 (Estimated)

Latest NLSP, JATT, MIRA, and BDRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/14/2025	Q1 2025	MIRA MIRA Pharmaceuticals	-$0.15	-$0.11	+$0.04	-$0.11	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BDRX Biodexa Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
JATT JATT Acquisition	N/A	N/A	N/A	N/A	N/A
MIRA MIRA Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
NLSP NLS Pharmaceutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BDRX Biodexa Pharmaceuticals	0.01	1.75	1.75
JATT JATT Acquisition	N/A	0.15	0.15
MIRA MIRA Pharmaceuticals	N/A	12.86	12.86
NLSP NLS Pharmaceutics	N/A	2.69	2.69

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BDRX Biodexa Pharmaceuticals	17.51%
JATT JATT Acquisition	47.97%
MIRA MIRA Pharmaceuticals	35.16%
NLSP NLS Pharmaceutics	N/A

Insider Ownership

Company	Insider Ownership
BDRX Biodexa Pharmaceuticals	0.34%
JATT JATT Acquisition	20.00%
MIRA MIRA Pharmaceuticals	6.65%
NLSP NLS Pharmaceutics	16.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BDRX Biodexa Pharmaceuticals	20	3.65 million	3.64 million	Not Optionable
JATT JATT Acquisition	3	17.25 million	13.80 million	Not Optionable
MIRA MIRA Pharmaceuticals	2	19.07 million	17.80 million	Not Optionable
NLSP NLS Pharmaceutics	6	3.60 million	3.01 million	Not Optionable

NLSP, JATT, MIRA, and BDRX Headlines

Recent News About These Companies

NLS Pharmaceutics (NASDAQ:NLSP) Upgraded at Wall Street Zen

August 12 at 3:13 AM | americanbankingnews.com

NLS Pharmaceutics Highlights Continued Progress in iTOL-102 Diabetes Program as BIRD Foundation Approves Additional Milestone Payment to Kadimastem and iTolerance for Continued Co-Development of Type 1 Diabetes Cell Therapy

July 17, 2025 | prnewswire.com

NLS Pharmaceutics and Kadimastem Announce Pricing and Closing of $1 Million Equity Financing

June 30, 2025 | prnewswire.com

NLS Pharmaceutics Ltd.: NLS Pharmaceutics CEO Issues Letter to Shareholders

June 18, 2025 | finanznachrichten.de

NLS Pharmaceutics CEO Issues Letter to Shareholders

June 16, 2025 | prnewswire.com

NLS Pharmaceutics to present Mazindol study at ASCP Meeting

May 22, 2025 | investing.com

NLS Pharmaceutics to Present New Data on the Dual Efficacy of Mazindol ER in Fentanyl Reward and Withdrawal at the 2025 ASCP Annual Meeting

May 21, 2025 | prnewswire.com

NLS Pharmaceutics Announces Positive Results from Study KO-943 Demonstrating Mazindol Reduces Fentanyl-Induced Reward in Animal Models

April 15, 2025 | prnewswire.com

NLS Pharmaceutics, Kadimastem announce up to $3M equity financing

April 1, 2025 | markets.businessinsider.com

NLS Pharmaceutics and Kadimastem Announces Up to $3 Million Equity Financing and $25 Million Equity Facility Agreement

March 31, 2025 | accessnewswire.comA

NLS Pharmaceutics CEO Issues Letter to Shareholders

March 10, 2025 | prnewswire.com

NLS Pharmaceutics announces new preclinical data for AEX-2

February 27, 2025 | markets.businessinsider.com

NLS Pharmaceutics Announces New Preclinical Data for AEX-2, Expanding the Therapeutic Potential of its Non-Sulfonamide Dual Orexin Receptor Agonist Platform

February 27, 2025 | prnewswire.com

NLS Pharmaceutics and Kadimastem complete pre-IND diabetes meeting with FDA

February 25, 2025 | markets.businessinsider.com

Kadimastem and iTolerance Successfully Complete Pre-IND Meeting with the FDA for its Type 1 Diabetes Treatment

February 25, 2025 | prnewswire.com

NLS Pharmaceutics files $75M mixed securities shelf

February 11, 2025 | markets.businessinsider.com

NLS and Kadimastem to merge, aim for diabetes care innovation

February 10, 2025 | msn.com

NLS Pharmaceutics and Kadimastem Unveil Multi-Target Approach to Diabetes, Expanding Beyond GLP-1 Therapies

February 10, 2025 | prnewswire.com

NLS Pharmaceutics files to sell 645,161 common shares for holders

February 5, 2025 | markets.businessinsider.com

NLS Pharmaceutics AG (NLSP) Stock: Analyzing Its Quiet Power

February 3, 2025 | bovnews.comB

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

NLSP, JATT, MIRA, and BDRX Company Descriptions

Biodexa Pharmaceuticals NASDAQ:BDRX

$6.91 -0.08 (-1.14%)

Closing price 03:59 PM Eastern

Extended Trading

$7.12 +0.22 (+3.11%)

As of 07:45 PM Eastern

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTD217, a program centered around a water-soluble drug formulation that can be easily infused or injected simultaneously, or sequentially, directly into the cancer microenvironment, currently under preclinical studies for the treatment of leptomeningeal disease. In addition, the company offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. It has collaboration agreements with Janssen and Melior. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.

JATT Acquisition NYSE:JATT

$1.47 +0.06 (+4.26%)

As of 08/12/2025

JATT Acquisition Corp does not have significant operations. It intends to effect a merger, capital share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company intends to focus on businesses primarily operating in the life sciences sector. JATT Acquisition Corp was incorporated in 2021 and is based in Grand Cayman, the Cayman Islands.

MIRA Pharmaceuticals NASDAQ:MIRA

$1.49 +0.02 (+1.36%)

Closing price 04:00 PM Eastern

Extended Trading

$1.50 +0.01 (+0.34%)

As of 07:39 PM Eastern

MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder. In addition, its oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Miami, Florida.

NLS Pharmaceutics NASDAQ:NLSP

$2.42 +0.29 (+13.62%)

Closing price 04:00 PM Eastern

Extended Trading

$2.43 +0.01 (+0.41%)

As of 07:54 PM Eastern

NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company also developing NLS-4, a selective dopamine reuptake inhibitor to prevent rare sleep disorders; NLS-3, a repurposed reverse ester of methylphenidate for treatment of ADHD; NLS-8, a melatonin ML1A receptor agonist, improved scopolamine-induced amnesia; NLS-11, a norepinephrine and dopamine reuptake inhibitor and muscarinic M1, M2, M3 receptor antagonist; and NLS-12, a norepinephrine and dopamine reuptake inhibitor and muscarinic M4 receptor antagonist. NLS Pharmaceutics AG was incorporated in 2015 and is based in Zurich, Switzerland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time